[Value of ambroxol in treatment of bronchial asthma and spastic bronchitis].
Ambroxol (Bronchopront-Mack) was administered to 73 patients with the bronchial asthma and spastic bronchitis with expectoration disorders. The drug was given in the dosage forms of slow release capsules, syrup, drops, intramuscular injections and inhalations for about 14 days. All patients have been carefully examined clinically, PEF has been measured, and sputum physico-chemical properties have been tested prior to and 10 days after treatment. Complete disappearance of cough, liquefaction of sputum and clearance of airways have been achieved in 47% of patients. A significant improvement has been noted in 38.4% of cases. The treatment failed in 2.7% of patients. Ambroxol has been well tolerated. No adverse effects on laboratory findings have been noted. Results suggest, that ambroxol is valuable drug in the combined treatment of patients with the bronchial asthma and spastic bronchitis.
Siergiejko
Z
Z
Kliniki Alergologii AM, Białymstoku.
Obrzut
D
D
Rogalewska
A
A
D000328:Adult; D000368:Aged; D000551:Ambroxol / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000551:Ambroxol
Przydatność ambroksolu w leczeniu astmy oskrzelowej i spastycznego niezytu oskrzeli.